scholarly journals Factors influencing long‐term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib

2015 ◽  
Vol 172 (1) ◽  
pp. 97-110 ◽  
Author(s):  
Tim H. Brümmendorf ◽  
Jorge E. Cortes ◽  
Hanna J. Khoury ◽  
Hagop M. Kantarjian ◽  
Dong‐Wook Kim ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Chronic Phase ◽  
Term Efficacy ◽  
Factors Influencing

scholarly journals Long‐term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE)

2020 ◽  
Vol 189 (2) ◽  
pp. 303-312 ◽  
Author(s):  
Young Rok Do ◽  
Jae‐Yong Kwak ◽  
Jeong A. Kim ◽  
Hyeoung Joon Kim ◽  
Joo Seop Chung ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Chronic Phase ◽  
Newly Diagnosed ◽  
Phase 3 ◽  
Term Data

scholarly journals Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience

2015 ◽  
Vol 170 (3) ◽  
pp. 398-407 ◽  
Author(s):  
Fiorina Giona ◽  
Maria C. Putti ◽  
Concetta Micalizzi ◽  
Giuseppe Menna ◽  
Maria L. Moleti ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Children And Adolescents ◽  
Myeloid Leukaemia ◽  
Chronic Phase ◽  
Long Term Results ◽  
High Dose ◽  
Italian Experience

scholarly journals Comparison of Response to Treatment with Imatinib Versus Nilotinib in the Initial Three Months in Chronic Myeloid Leukaemia

2021 ◽  
Vol 8 (24) ◽  
pp. 2001-2005
Author(s):  
Irom Anil Singh ◽  
Aditi Jain ◽  
Pukhrambam Vedanti Devi ◽  
Tombing Niangneihching
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Kinase Inhibitors ◽  
Chronic Phase ◽  
Response To Treatment ◽  
P Value ◽  
Molecular Response ◽  
Optimal Response ◽  
Potent Drug

BACKGROUND Chronic myeloid leukemia (CML) accounts for 15 - 20 % of leukemia in adults worldwide. At present, the three tyrosine kinase inhibitors (TKI) imatinib, dasatinib, or nilotinib are accepted as the standard first-line treatment in chronic phase (CP). Nilotinib is a second generation TKI having faster and deeper response compared to imatinib. We wanted to see if the response achieved with nilotinib in the first three months could be translated into long term benefits when imatinib was given after 3 months. METHODS Newly diagnosed CML-CP patients were randomized into two arms. The patients on the first arm were given imatinib and in the second arm nilotinib was given for first 3 months. After three months nilotinib was switched over to imatinib. The molecular response was assessed in both arms at 3 months and 6 months. RESULTS Twenty-six patients in each arm were analysed. The optimal molecular response (QPCR <10 %) after 3 months was significantly higher in patients receiving nilotinib than imatinib (96.1 % vs 65.38 %; P < 0.0048). The optimal response after 6 months (QPCR < 1 %) was found to be more in the initial nilotinib arm than the initial imatinib arm (76.9 % vs 65.3 %; P - value = 0.35). CONCLUSIONS Patients on nilotinib arm did well even after switching to imatinib. It gives us an important platform for an economically backward country like India where the therapy with more potent drug like nilotinib is given in the initial three months or even six months. KEYWORDS Chronic Myeloid Leukaemia, Imatinib, Nilotinib, Optimal Response, Major Molecular Response

scholarly journals Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Yotaro Ochi ◽  
Kenichi Yoshida ◽  
Ying-Jung Huang ◽  
Ming-Chung Kuo ◽  
Yasuhito Nannya ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Kinase Inhibitors ◽  
Blast Crisis ◽  
Clonal Evolution ◽  
Chronic Phase ◽  
Genetic Alterations ◽  
Prognostic Impact ◽  
Genetic Abnormalities ◽  
Prior Use

AbstractBlast crisis (BC) predicts dismal outcomes in patients with chronic myeloid leukaemia (CML). Although additional genetic alterations play a central role in BC, the landscape and prognostic impact of these alterations remain elusive. Here, we comprehensively investigate genetic abnormalities in 136 BC and 148 chronic phase (CP) samples obtained from 216 CML patients using exome and targeted sequencing. One or more genetic abnormalities are found in 126 (92.6%) out of the 136 BC patients, including the RUNX1-ETS2 fusion and NBEAL2 mutations. The number of genetic alterations increase during the transition from CP to BC, which is markedly suppressed by tyrosine kinase inhibitors (TKIs). The lineage of the BC and prior use of TKIs correlate with distinct molecular profiles. Notably, genetic alterations, rather than clinical variables, contribute to a better prediction of BC prognosis. In conclusion, genetic abnormalities can help predict clinical outcomes and can guide clinical decisions in CML.

Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial

2021 ◽  
Vol 8 (12) ◽  
pp. e902-e911 ◽  
Author(s):  
Kazunori Murai ◽  
Hiroshi Ureshino ◽  
Takashi Kumagai ◽  
Hideo Tanaka ◽  
Kaichi Nishiwaki ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Older Patients ◽  
Low Dose ◽  
Chronic Phase ◽  
Phase 2 ◽  
Multicentre Phase ◽  
Phase 2 Trial
Sign in / Sign up

Export Citation Format

Share Document